trial

Pentoxifylline Add-on Therapy for Schizophrenia

NCTId NCT05073640
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Unknown
Enrollment 90 (estimated)
Sponsored by Mazra Mental Health Center
Primary completion 2022-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Unknown
Enrollment
90 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2019-04-20
Primary completion
2022-04
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Oxopurin

Sponsors

Mazra Mental Health CenterLead Sponsor
Ben-Gurion University of the NegevCollaborator

Sites

1 total
Acre, Israel

Linked catalysts

1
Pentoxifylline Add-on Therapy for Schizophrenia — primary completion2022-04

Facts & assertions

4 sourced
Enrollment
90
Phase
PHASE1,PHASE2
Primary Completion Date
2022-04
Status
UNKNOWN
relationships
The graph out of here
drug
Oxopurin
drug
lead_sponsor
Mazra Mental Health Center
company
collaborator
Ben-Gurion University of the Negev
company
indication
Schizophrenia
indication
Schizophrenia
indication